Infinity Winnows Pipeline After Phase II Retaspimycin Miss

Focus at Infinity Pharmaceuticals Inc., which had shifted in the wake of disappointing data from its Hedgehog inhibitor program in early 2012, narrowed further this week following a Phase II miss with heat-shock protein 90 (Hsp90) inhibitor retaspimycin hydrochloride in non-small-cell lung cancer (NSCLC).